Hepion pharmaceuticals announces passing of key safety milestone in phase 2b ‘ascend-nash' trial of rencofilstat

Edison, n.j., june 15, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that the data and safety monitoring board (“dsmb”) has met to review the current data for the ascend-nash phase 2b trial and has issued a “study may proceed without modification” clearance.
HEPA Ratings Summary
HEPA Quant Ranking